共 308 条
[1]
Freddie B(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Jacques F(2017)The role of systemic therapy in resectable gastric and gastro-oesophageal junction cancer Curr Treat Options Oncol 18 69-108
[3]
Isabelle S(2016)S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial Lancet Oncol 17 99-5768
[4]
Cartwright E(2017)Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer Clin Cancer Res 23 5757-34831
[5]
Cunningham D(2016)Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: a meta-analysis of randomized controlled trials Oncotarget 7 34824-1355
[6]
Hironaka S(2016)Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy Oncol Rep 35 1349-241
[7]
Sugimoto N(2016)The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis J Chemother 28 235-715
[8]
Yamaguchi K(2014)A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy Cancer Treat Rev 40 701-3116
[9]
Dolan ME(2009)Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109-262
[10]
El CO(2013)The complexity of adverse side-effects to biological agents J Crohns Colitis 7 257-514